Micelle 60

Development product sheet | Version 1.0 | Status checked October 1, 2026

Micelle 60 is a hemp-derived CBD isolate softgel in development. The **planned** label amount is 60 mg CBD per softgel; the planned pack contains 60 softgels. It is not a released product, a clinical recommendation, a laboratory certificate or an assertion of CMS eligibility.

Product description

Field	Current statement or status
Form	Softgel in development; final formulation and excipient list Pending.
CBD source	Hemp-derived CBD isolate planned; genuine ingredient identity and purity certificates Pending.
Planned label amount	60 mg CBD per softgel; target, not a measured release result.
Planned pack	60 softgels per bottle; label artwork is a draft, not approved packaging.
Route	Planned oral softgel. No dosing regimen, clinical effect or condition-specific use established here.
Separate program	NW PharmaTech's 300 mg investigational product is different; no evidence or outcome is transferred to Micelle 60.

Fields requiring controlled specification and release evidence

Control area	Evidence required; current status
Identity and potency	Finished-product identity, CBD assay, units, acceptance range, method and batch record: Pending. Potency is measured against an approved specification; it is not expected to be "negative".
Total THC basis	Combined tetrahydrocannabinols per finished container, including THCA, methods and limits: Pending. A planned less-than-0.4 mg target alone proves neither compliance nor CMS eligibility.
Contaminants / microbes	Third-party contaminant and microbial panels, methods, detection limits and qualifying negative results: Pending. These are distinct from potency measurements.
Other controls	Other cannabinoids, residual solvents, pesticides, elemental impurities, stability, storage, shelf life, manufacturer and approved release criteria: Pending.
Traceability	Real lot identifiers, approved labels, finished-product certificate, notice process and change history: Pending. Current Quality Passport lot records are Example data only.

Content is under review. Read the dated readiness register and product specification page for current supporting records. For organization review, request a briefing. Do not send patient information.